{"filing":{"accession_number":"0001193125-26-240645","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"d129501d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/d129501d8k.htm"},"events":[{"id":8718,"run_id":7655,"accession_number":"0001193125-26-240645","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Jaguar Health regained compliance with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)) as of May 26, 2026, but remains subject to a mandatory one-year Panel Monitor period with a critical condition: failure to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days would result in immediate delisting without the standard 180-day grace period.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-05-27","submitted_at":null,"items":[{"id":1886,"accession_number":"0001193125-26-240645","item_number":"7.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a \"Decision Letter\" from the Nasdaq Hearings Panel, which is the formal mechanism through which Nasdaq communicates listing compliance determinations, including delisting notices or continued listing status. A Nasdaq Hearings Panel decision letter is material to investors as it directly addresses whether the company maintains its exchange listing. This disclosure under Item 7.01 (Regulation FD Disclosure) indicates a significant corporate governance or listing status event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:13:11.548420+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1887,"accession_number":"0001193125-26-240645","item_number":"8.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on Jaguar Health's compliance status with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)). While the company has regained compliance as of May 26, 2026, it remains subject to a mandatory one-year Panel Monitor period with a critical condition: failure to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days would result in immediate delisting without the standard 180-day grace period. This represents a material delisting risk that would significantly affect investor assessment of the company's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:13:11.548420+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1886,"accession_number":"0001193125-26-240645","item_number":"7.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a \"Decision Letter\" from the Nasdaq Hearings Panel, which is the formal mechanism through which Nasdaq communicates listing compliance determinations, including delisting notices or continued listing status. A Nasdaq Hearings Panel decision letter is material to investors as it directly addresses whether the company maintains its exchange listing. This disclosure under Item 7.01 (Regulation FD Disclosure) indicates a significant corporate governance or listing status event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:13:11.548420+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-05-27"},{"id":1887,"accession_number":"0001193125-26-240645","item_number":"8.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on Jaguar Health's compliance status with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)). While the company has regained compliance as of May 26, 2026, it remains subject to a mandatory one-year Panel Monitor period with a critical condition: failure to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days would result in immediate delisting without the standard 180-day grace period. This represents a material delisting risk that would significantly affect investor assessment of the company's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:13:11.548420+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-05-27"}]}